Yung Lee

Dr. Yung Lee


Research Focus & Metrics

Representative Publications

View All Publications
1 May 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
Yung LeeYung Lee
Yung Lee
ADAristithes G. Doumouras
Aristithes G. Doumouras
JYJames Yu
James Yu
KBKaranbir Brar
Karanbir Brar
LBLaura Banfield
Laura Banfield
DHDennis Hong
Dennis Hong

13 April 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
ADAristithes G. Doumouras
Aristithes G. Doumouras
JWJorge A. Wong
Jorge A. Wong
JPJ. Michael Paterson
J. Michael Paterson
Yung LeeYung Lee
Yung Lee
BSBranavan Sivapathasundaram
Branavan Sivapathasundaram
MAMehran Anvari
Mehran Anvari
Background: Bariatric surgery has been shown to significantly reduce cardiovascular risk factors. However, whether surgery can reduce major adverse cardiovascular events (MACE), especially in patients with established cardiovascular disease, remains poorly understood. The present study aims to determine the association between bariatric surgery and MACE among patients with cardiovascular disease and severe obesity. Methods: This was a propensity score–matched cohort study using province-wide multiple-linked administrative databases in Ontario, Canada. Patients with previous ischemic heart disease or heart failure who received bariatric surgery were matched on age, sex, heart failure history, and a propensity score to similar controls from a primary care medical record database in a 1:1 ratio. The primary outcome was the incidence of extended MACE (first occurrence of all-cause mortality, myocardial infarction, coronary revascularization, cerebrovascular events, and heart failure hospitalization). Secondary outcome included 3-component MACE (myocardial infarction, ischemic stroke, and all-cause mortality). Outcomes were evaluated through a combination of matching via propensity score and subsequent multivariable adjustment. Results: A total of 2638 patients (n=1319 in each group) were included, with a median follow-up time of 4.6 years. The primary outcome occurred in 11.5% (151/1319) of the surgery group and 19.6% (259/1319) of the controls (adjusted hazard ratio [HR], 0.58 [95% CI, 0.48–0.71]; P <0.001). The association was notable for those with heart failure (HR, 0.44 [95% CI, 0.31–0.62]; P <0.001; absolute risk difference, 19.3% [95% CI, 12.0%–26.7%]) and in those with ischemic heart disease (HR, 0.60 [95% CI, 0.48–0.74]; P <0.001; absolute risk difference, 7.5% [95% CI, 4.7%–10.5%]). Surgery was also associated with a lower incidence of the secondary outcome (HR, 0.66 [95% CI, 0.52–0.84]; P =0.001) and cardiovascular mortality (HR, 0.35 [95% CI, 0.15–0.80]; P =0.001). Conclusions: Bariatric surgery was associated with a lower incidence of MACE in patients with cardiovascular disease and obesity. These findings require confirmation by a large-scale randomized trial.


3 November 2020 in Annals of Internal Medicine
Verified
Journal Article
Closed access
ADAristithes G. Doumouras
Aristithes G. Doumouras
DHDennis Hong
Dennis Hong
Yung LeeYung Lee
Yung Lee
JTJean-Eric Tarride
Jean-Eric Tarride
JPJ. Michael Paterson
J. Michael Paterson
MAMehran Anvari
Mehran Anvari
Previous observational studies have found a substantially lower long-term mortality risk associated with bariatric surgery, but selection bias and residual confounding remain a concern. This large ... Visual Association Between Bariatric Surgery and All-Cause Mortality Previous observational studies have found a substantially lower long-term mortality risk associated with bariatric surg... Background: Mortality after bariatric surgery has been previously studied, but cohort selection bias, completeness of follow-up, and collection of confounders have limited the inference of results....

13 March 2023 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
TSTino Singh
Tino Singh
LLLauri I Lavikainen
Lauri I Lavikainen
AHAlex L E Halme
Alex L E Halme
RARiikka Aaltonen
Riikka Aaltonen
AAArnav Agarwal
Arnav Agarwal
KTKari A O Tikkinen
Kari A O Tikkinen
Background: The timing at which venous thromboembolism (VTE) occurs after major surgery has major implications for the optimal duration of thromboprophylaxis. The aim of this study was to perform a systematic review and meta-analysis of the timing of postoperative VTE up to 4 weeks after surgery. Methods: A systematic search of MEDLINE, Scopus, and CINAHL databases was performed between 1 January 2009 and 1 April 2022. Prospective studies that recruited patients who underwent a surgical procedure and reported at least 20 symptomatic, postoperative VTE events by time were included. Two reviewers independently selected studies according to the eligibility criteria, extracted data, and evaluated risk of bias. Data were analysed with a Poisson regression model, and the GRADE approach was used to rate the certainty of evidence. Results: Some 6258 studies were evaluated, of which 22 (11 general, 5 urological, 4 mixed, and 2 orthopaedic postoperative surgical populations; total 1 864 875 patients and 24 927 VTE events) were eligible. Pooled evidence of moderate certainty showed that 47.1 per cent of the VTE events occurred during the first, 26.9 per cent during the second, 15.8 per cent during the third, and 10.1 per cent during the fourth week after surgery. The timing of VTE was consistent between individual studies. Conclusion: Although nearly half of symptomatic VTE events in first 4 weeks occur during the first postoperative week, a substantial number of events occur several weeks after surgery. These data will inform clinicians and guideline developers about the duration of postoperative thromboprophylaxis.

8 August 2023 in Annals of Surgery
Verified
Journal Article
Open access
LLLauri I. Lavikainen
Lauri I. Lavikainen
Gordon H. GuyattGordon H. Guyatt
Gordon H. Guyatt
VSVille Sallinen
Ville Sallinen
PKPaul Jack Karanicolas
Paul Jack Karanicolas
RCRachel J. Couban
Rachel J. Couban
RTRiikka M. Tähtinen
Riikka M. Tähtinen
Objective: To provide procedure-specific estimates of symptomatic venous thromboembolism (VTE) and major bleeding after abdominal surgery. Background: The use of pharmacological thromboprophylaxis represents a trade-off that depends on VTE and bleeding risks that vary between procedures; their magnitude remains uncertain. Methods: We identified observational studies reporting procedure-specific risks of symptomatic VTE or major bleeding after abdominal surgery, adjusted the reported estimates for thromboprophylaxis and length of follow-up, and estimated cumulative incidence at 4 weeks postsurgery, stratified by VTE risk groups, and rated evidence certainty. Results: After eligibility screening, 285 studies (8,048,635 patients) reporting on 40 general abdominal, 36 colorectal, 15 upper gastrointestinal, and 24 hepatopancreatobiliary surgery procedures proved eligible. Evidence certainty proved generally moderate or low for VTE and low or very low for bleeding requiring reintervention. The risk of VTE varied substantially among procedures: in general abdominal surgery from a median of <0.1% in laparoscopic cholecystectomy to a median of 3.7% in open small bowel resection, in colorectal from 0.3% in minimally invasive sigmoid colectomy to 10.0% in emergency open total proctocolectomy, and in upper gastrointestinal/hepatopancreatobiliary from 0.2% in laparoscopic sleeve gastrectomy to 6.8% in open distal pancreatectomy for cancer. Conclusions: VTE thromboprophylaxis provides net benefit through VTE reduction with a small increase in bleeding in some procedures (eg, open colectomy and open pancreaticoduodenectomy), whereas the opposite is true in others (eg, laparoscopic cholecystectomy and elective groin hernia repairs). In many procedures, thromboembolism and bleeding risks are similar, and decisions depend on individual risk prediction and values and preferences regarding VTE and bleeding.